Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 6/20 | 0.42 |
| ▸ | SNCA | P37840 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Broparestrol SCHEMBL29375131 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TP53SMN1; SMN2ESR1SNCA | |
| SCHEMBL1049697 | 0.81 | CES1 (0.41) | ALDH1A1SMN1; SMN2ESR1CES2CES1 | |
| SCHEMBL21241545 | 0.81 | CES2 (0.58) | ALDH1A1TP53SMN1; SMN2ESR1SNCA | |
| Phosphine SCHEMBL5051760 | 0.79 | CES1 (0.39) | ALDH1A1SMN1; SMN2ESR1CES2CES1 | |
| SCHEMBL14361865 | 0.77 | TP53 (0.59) | ALDH1A1TP53SMN1; SMN2CES2CES1 | |
| SCHEMBL21241003 | 0.77 | ALDH1A1 (0.48) | ALDH1A1TP53SMN1; SMN2ESR1SNCA | |
| SCHEMBL31163188 | 0.77 | LTA4H (0.52) | TP53SMN1; SMN2ESR1CYP19A1ESR2 | |
| SCHEMBL24350341 | 0.74 | NPC1 (0.41) | SMN1; SMN2ESR1CES2CES1 | |
| SCHEMBL9859914 | 0.74 | NPC1 (0.41) | SMN1; SMN2ESR1CES2CES1 | |
| SCHEMBL975055 | 0.74 | ALDH1A1 (0.65) | ALDH1A1TP53SMN1; SMN2PLK1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 463 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380364-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-12-01 | — | — | US | claimed |
| CN-111148764-A | Combinations of ErbB-2/ErbB-3 bispecific antibodies and endocrine therapy for breast cancer | 美勒斯公司 | 2020-05-12 | — | — | CN | claimed |
| EP-3625264-A1 | COMBINATION OF AN ERBB-2/ERBB-3 BISPECIFIC ANTIBODY WITH ENDOCRINE THERAPY FOR BREAST CANCER | Merus N.V. (NL) | 2020-03-25 | — | — | EP | claimed |
| US-20190000830-A1 | INHIBITION AND TREATMENT OF BACTERIAL INFECTIONS BY SEX-SPECIFIC GPER TARGETING | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2019-01-03 | — | — | US | claimed |
| WO-2018212656-A1 | COMBINATION OF AN ERBB-2/ERBB-3 BISPECIFIC ANTIBODY WITH ENDOCRINE THERAPY FOR BREAST CANCER | MERUS N.V. (NL) | 2018-11-22 | — | — | WO | claimed |
| WO-2017123492-A1 | INHIBITION AND TREATMENT OF BACTERIAL INFECTIONS BY SEX-SPECIFIC GPER TARGETING | STC. UNM (US) | 2017-07-20 | — | — | WO | claimed |
| US-20130323187-A1 | SYNTHETIC PEPTIDES FOR USE AS INHIBITORS OF NEUROTRANSMITTER SECRETION AND AS INDUCERS OF CELLULAR RELAXATION | PARTNERSHIP & CORP. TECHNOLOGY TRANSFER (CH) | 2013-12-05 | — | — | US | claimed |
| US-8318898-B2 | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation | UNIVERSITE DE LAUSANNE (CH) | 2012-11-27 | — | — | US | claimed |
| EP-2331707-A2 | DETERMINING AGE RANGES OF SKIN SAMPLES | Dermtech International (US) | 2011-06-15 | — | — | EP | claimed |
| US-20100086501-A1 | Determining Age Ranges of Skin Samples | DERMTECH INTERNATIONAL (US) | 2010-04-08 | — | — | US | claimed |
| US-20030228266-A1 | Topical applying thymosin | JAN MARINI SKIN RESEARCH, INC. | 2003-12-11 | — | — | US | claimed |
| EP-1369107-A1 | Cosmetic skin care compositions | Jan Marini Skin Research Inc. (US) | 2003-12-10 | — | — | EP | claimed |
| US-20030130244-A1 | Compositions for treatment of postmenopausal female sexual dysfunction | PHARMACIA CORPORATION | 2003-07-10 | — | — | US | claimed |
| WO-2003039553-A1 | COMPOSITIONS FOR TREATMENT OF POSTMENOPAUSAL FEMALE SEXUAL DYSFUNCTION | PHARMACIA CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
| EP-1203579-A1 | Cosmetic skin care compositions containing alpha interferon | Jan Marini Skin Research Inc. (US) | 2002-05-08 | — | — | EP | claimed |
| US-6328987-B1 | FOR DAMAGED SKIN (DUE TO AGING, SUN EXPOSURE, ETC) | JAN MARINI SKIN RESEARCH, INC. | 2001-12-11 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5989568-A | TREATING WRINKLES AND FINE LINES | L'OREAL (FR) | 1999-11-23 | — | — | US | claimed |
| US-5900242-A | TOPICALLY APPLYING DEHYDRO-EPI-ANDROSTERONE SULFATE MIXTURE TO REVIVE RADIANCE OF HUMAN SKIN | SOCIETE L'OREAL S.A. (FR) | 1999-05-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380364-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | ALDH1A1 3398/4885TP53 55/4885SMN1; SMN2 4588/4885 |
| US-20190000830-A1 | INHIBITION AND TREATMENT OF BACTERIAL INFECTIONS BY SEX-SPECIFIC GPER TARGETING | GPER1, GPBAR1, ESR1 | ALDH1A1 2770/4885TP53 3972/4885SMN1; SMN2 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.